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survivors than non-survivors is not surprising. For 
instance, in seven cases death followed withdrawal of 
mechanical ventilation. Was early tracheostomy practised? 
This increasingly is recognized to enable earlier discharge 
from the ICU. 
It is difficult to evaluate quality of life in chronic illness. 
Dependency does not equate with reduced quality (4). A 
better evaluation would have been to interview survivors 
and ascertain whether they would opt for mechanical 
ventilation again. Other series (5), involving a much larger 
number of patients, suggest a better outcome than is 
reported here. 
As with previous studies, analysis of prognostic 
indicators demonstrates that there are no sensitive 
measures and that an ‘on the spot’ decision, leaning 
towards provision of mechanical ventilation, is justified. 
NIV should be employed unless contra indications exist. 
If it fails to reverse the spiral towards intubation, it may 
be employed to speed weaning following a short period of 
MV. Surely this is a more appropriate way to care for our 
patients than the nihilistic one suggested by Dr Hill and 
colleagues. 
DR A. C. DAVIDSON* AND 
DR D. F. TREACHERY 
“Consultant Physician, 
Intensive Care and Respiratory Medicine 
‘Director of Intensive Care and Consultant Physician, 
Guy’s and St. Thomas’ Hospital Trust, 
London, U.K. 
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Reply to Drs Davidson and Treacher 
The letter by Davidson and Treacher suggests that the 
paper by Hill et al. (Respir Med 1998; 92: 156161) makes 
for depressing reading and suggests that other series 
show better outcomes. Our series revealed a 49% hospital 
mortality and 59% 1 year mortality: similar outcomes 
were found in U.S. and more recent U.K. studies. In the 
SUPPORT study (1) the 180 day mortality for 348 venti- 
lated patients was 43% (1 year mortality not reported) but 
in another large U.S. study (2), 1 year follow-up was 
available on 167 ventilated COPD patients and in this 
series hospital mortality was 30%, 180 day mortality 48%, 
and 1 year mortality identical to our series at 59%. The 
largest U.K. series by Wildman et al. (3) of 242 ventilated 
COPD patients reports a hospital mortality of 34.2% and 
180 day mortality of 35.5% (1 year mortality data not yet 
reported). We would not agree with the suggestion that 
the article will ‘reinforce the prejudice in the U.K. against 
intubation and ventilation in acute exacerbations of 
COPD’. Davidson and Treacher seem to have missed the 
point of the study which was to stratify a complex case 
mix and identify factors that could prejudice poor out- 
come in 1993 when there was little discussion of this 
important topic in the U.K. 
The low use of NIPPV in our series reflects evidence- 
based practice appropriate to the study period between 
1993 and 1995. At that time the Bott paper (4) had been 
published suggesting the potential for NIPPV within clini- 
cal trials, but did not provide a secure evidence base for its 
wholesale adoption. The subsequent randomized controlled 
trials suggesting a role for NIPPV were not published until 
1995 (5,6) and we agree with the two authors that the ICU 
management of COPD patients will not involve NIPPV, 
with data likely to emerge soon to help decide its role 
outside the ITU. 
Davidson and Treacher question whether admission was 
delayed leading to an increase in mortality and whether 
early tracheostomy was practised in the series by Hill et al. 
The paper did look at whether being admitted to ITU on 
the day of hospital admission influenced outcome. In this 
study there was no difference in outcome whether being 
admitted directly to ITU or following deterioration with 
medical therapy from a medical ward. Tracheostomy was 
and is practised in our intensive care unit if there are 
no signs of ability to wean early and earlier still if 
trachea-bronchial toilet is a problem. 
Davidson and Treacher comment that lack of medical 
documentation should not be taken to indicate that treat- 
ment options were not discussed with patients or relatives, 
and question whether this would influence ICU admission. 
The courts would not necessarily agree with this; what is 
not recorded possibly has not been done-present views 
are not to give professionals the benefit of the doubt where 
medical records are concerned. Discussion can certainly 
influence decision making, for example, one would be more 
likely to ventilate someone with a good pre-morbid history 
without co-morbidities. 
We would restate our contention that the high absolute 
and opportunity costs along with the significant morbidity 
and mortality in this group emphasizes the need for further 
prospective studies to better identify the patients who 
will benefit. We are presently initiating such a study at 
Birmingham Heartlands Hospital and preliminary results 
are expected later in 1999. 
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Dear Editor 
Corticosteroid treatment of asthma: 
now at the crossroads 
I read with interest the observation of Seale and Donnelly 
(1) on the relative systemic activity of fluticasone proprio- 
nate (FP) and budesonide (BUD). This is based on studies 
in healthy volunteers. In a previous meta-analysis of studies 
performed in patients with asthma (2), I noted that if 
anything the effect was the opposite of the one they 
describe. 
In order to address this apparent contradiction, I per- 
formed an analysis to consolidate the large volume of 
literature comparing the systematic effects on the HPA axis 
of FP versus BUD in healthy volunteers and asthmatics. To 
test the hypothesis that observations of systemic effects in 
volunteers may not predict the outcome in patients, I 
carried out a review of all studies of FP and BUD published 
to date which measured effects on cortisol(3-25). To avoid 
bias, data were selected only where both FP and BUD were 
compared in the same study. Use of plasma and urine 
samples and measurements of both AUC cortisol and AM 
cortisol, compared either to baseline or placebo, were 
reported. Where multiple measures were reported in a 
study, urine or plasma area under the curve and change 
from placebo was selected in preference to the less sensitive 
morning plasma cortisol data. 
For the purpose of the analysis, the effect of any dose of 
FP or BUD on cortisol levels was assessed by using the 
residual level of cortisol remaining at the end of treatment 
expressed as a percentage of baseline (or placebo response). 
BUD and FP were then compared within each study using 
the ratio of the respective residual percentages; ratios 
greater than 1 indicate FP suppression greater than BUD. 
Data were used only from the highest dose pair of FP and 
BUD in any study. Table 1 shows the resulting doses 
compared and effect on co&sol levels together with their 
weighted (by group size) means. 
At approximately equal doses, these results confirm that 
in healthy volunteers, FP gives rise to higher levels of 
cortisol suppression than BUD (BUD/FP ratio=3.3). How- 
ever in asthmatic patients, FP and BUD result in equal 
effects on the HPA axis (BUD/FP ratio= 1.0). 
These data suggest a difference in the relative systemic 
exposure of healthy volunteers and asthmatic patients to 
FP and BUD. This is consistent with pharmacokinetic data 
which have shown that volunteers have two-fold higher FP 
levels than patients with asthma (26). From these pharma- 
cokinetic data, one could infer a reduction in lung absorp- 
tion in asthmatic patients which, given the negligible oral 
bioavailability of FP, would lead to a low systemic expo- 
sure to FP but not BUD as was observed in the current 
analysis. I conclude that studies of systemic exposure in 
healthy volunteers may not reflect the clinical outcome in 
patients. However, specifically designed studies should be 
used to test this hypothesis. 
C. HALLETT, B.Sc., CSTAT. 
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